Company Filing History:
2 out of 82 
2 out of 4,455 
1 out of 40 Years Active: 1993-1995
Title: Innovations of Robin J Andy in Diabetes Treatment
Introduction
Robin J Andy is an accomplished inventor based in Cupertino, CA (US). He has made significant contributions to the field of diabetes treatment through his innovative work on insulin analogs. With a total of 2 patents, his research focuses on developing tissue-selective insulin analogs that offer superior clinical benefits for patients suffering from diabetes.
Latest Patents
Robin J Andy's latest patents include a method of treating diabetes with tissue-selective insulin analogs. These human insulin analogs are designed to be tissue-selective, providing enhanced clinical outcomes compared to traditional human insulin. The analogs are modified at amino residues A12, A15, or A19, differing from the naturally occurring residues at these positions, and exhibit hepatoselective properties. Additionally, the patents disclose human insulin analogs modified at amino acid residues A12 or A14, or residues A10 and A13, which are peripheral selective. The patents also include DNA sequences and microorganisms that code for these human insulin analogs, along with processes for their preparation.
Career Highlights
Throughout his career, Robin J Andy has worked with notable companies such as Scios Inc. and Pfizer Corporation. His experience in these organizations has contributed to his expertise in the development of pharmaceutical formulations and innovative treatments for diabetes.
Collaborations
Robin has collaborated with various professionals in the field, including his coworker Eric R Larson. Their joint efforts have further advanced the research and development of insulin analogs.
Conclusion
Robin J Andy's innovative work in the field of diabetes treatment through tissue-selective insulin analogs showcases his dedication to improving patient care. His contributions are significant in the ongoing quest for better therapeutic options for diabetes management.